-+ 0.00%
-+ 0.00%
-+ 0.00%

Can CVS Health (CVS) Stay Below Fair Value After Recent News?

Simply Wall St·11/20/2026 02:11:41
Listen to the news

CVS Health shares have held roughly flat year to date after a 29.6% gain over three years, and that mixed share price story puts the focus squarely on what investors are paying for the company’s earnings today. With fresh headlines ranging from drug affordability studies to legal settlements and technology awards, the immediate question is whether the current valuation still lines up with the profit engine behind the business.

  • The 29.6% return over three years has rewarded patience, which raises the stakes on whether ongoing earnings can support the price that performance has delivered.
  • Recent work on GLP-1 therapies and biosimilars, along with legal and regulatory developments, can influence future profitability by affecting drug pricing power, pharmacy costs and the mix of earnings across CVS Health’s healthcare and retail operations.
  • The analysts covering CVS Health have run their own numbers. See what analysts think CVS Health's shares could be worth.

The issue now is whether CVS Health's current share price is justified by the earnings the business is generating today and is expected to produce over time.

If you want to review CVS Health's earnings story alongside other potential ideas, a focused screen of 36 healthcare AI stocks can be a useful next step in your research.

Does CVS Health Look Undervalued on Earnings?

P/E is a useful lens for CVS Health because earnings still sit at the center of how investors judge large healthcare groups with both retail and insurance exposure. The stock currently trades on a P/E of 9.3x, compared with about 25.1x for the broader healthcare industry and 19.5x for its peer group, so the market is applying a much lower earnings multiple to CVS Health than to many comparable businesses.

Because the model based on CVS Health's own growth profile, margins, scale and risk suggests a higher P/E would be typical, this discount versus the tailored fair level screens as undervalued on this metric. Despite recent attention on GLP-1 affordability challenges and legal settlements, the current P/E still prices CVS Health materially below both healthcare peers and what the model implies for a business with its earnings power. Explore the numbers behind CVS Health's P/E valuation.

NYSE:CVS P/E Ratio as at Nov 2026
NYSE:CVS P/E Ratio as at Nov 2026

The CVS Health Narrative: What Would Justify Today's Price?

Narratives on CVS Health pick up where the P/E question leaves off and outline which combinations of future growth, profitability and earnings power would need to occur for the stock to be worth meaningfully more or less than it is today. These are based on scenarios you can track over time on Simply Wall St's Community page. Each one treats fair value as a concrete thesis about CVS Health's business that you can observe over time against new information, rather than a one-time snapshot.

One of the top community narratives on CVS Health: 23% undervalued

According to yiannisz, an investor in the Simply Wall St Community who wrote the Narrative, CVS Health is a complex turnaround story that hinges on execution.

"CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss..."

Discover why this Narrative puts CVS Health at 23% undervalued.

CVS Health’s valuation still hinges on one unresolved risk question

Price and earnings only tell part of the CVS Health story, because the latest research has flagged specific concerns that could change how you think about this business. Take a closer look at 1 warning sign before settling on a valuation.